SI3723807T1 - Kombinirana zdravljenja, ki obsegajo dajanje 1H-pirazolo(4,3-b)piridinov - Google Patents

Kombinirana zdravljenja, ki obsegajo dajanje 1H-pirazolo(4,3-b)piridinov

Info

Publication number
SI3723807T1
SI3723807T1 SI201830453T SI201830453T SI3723807T1 SI 3723807 T1 SI3723807 T1 SI 3723807T1 SI 201830453 T SI201830453 T SI 201830453T SI 201830453 T SI201830453 T SI 201830453T SI 3723807 T1 SI3723807 T1 SI 3723807T1
Authority
SI
Slovenia
Prior art keywords
pyrazolo
pyridines
administration
combination treatments
treatments
Prior art date
Application number
SI201830453T
Other languages
English (en)
Inventor
Jan Kehler
Karsten Juhl
Mauro Marigo
Paulo Jorge Vieira Vital
Mikkel Jessing
Morten Langgard
Lars Kyhn Rasmussen
Carl Martin Sebastian Clementson
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of SI3723807T1 publication Critical patent/SI3723807T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201830453T 2017-12-14 2018-12-12 Kombinirana zdravljenja, ki obsegajo dajanje 1H-pirazolo(4,3-b)piridinov SI3723807T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201700708 2017-12-14
PCT/EP2018/084432 WO2019115566A1 (en) 2017-12-14 2018-12-12 Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
EP18830163.4A EP3723807B1 (en) 2017-12-14 2018-12-12 Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines

Publications (1)

Publication Number Publication Date
SI3723807T1 true SI3723807T1 (sl) 2022-01-31

Family

ID=64959282

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830453T SI3723807T1 (sl) 2017-12-14 2018-12-12 Kombinirana zdravljenja, ki obsegajo dajanje 1H-pirazolo(4,3-b)piridinov

Country Status (26)

Country Link
US (1) US11634416B2 (sl)
EP (1) EP3723807B1 (sl)
JP (1) JP7261801B2 (sl)
KR (1) KR20200099154A (sl)
CN (1) CN111465410B (sl)
AR (1) AR113931A1 (sl)
AU (1) AU2018385453B2 (sl)
BR (1) BR112019016815A2 (sl)
CA (1) CA3085201A1 (sl)
CL (1) CL2020001548A1 (sl)
CO (1) CO2020007129A2 (sl)
CY (1) CY1124751T1 (sl)
ES (1) ES2899868T3 (sl)
HR (1) HRP20211784T1 (sl)
HU (1) HUE057202T2 (sl)
IL (1) IL275290B2 (sl)
LT (1) LT3723807T (sl)
MX (1) MX2020006174A (sl)
PL (1) PL3723807T3 (sl)
PT (1) PT3723807T (sl)
RS (1) RS62551B1 (sl)
RU (1) RU2020118913A (sl)
SG (1) SG11202005361RA (sl)
SI (1) SI3723807T1 (sl)
WO (1) WO2019115566A1 (sl)
ZA (1) ZA202003514B (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
WO2019115566A1 (en) 2017-12-14 2019-06-20 H. Lundbeck A/S Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US11535611B2 (en) 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
DE19942474A1 (de) 1999-09-06 2001-03-15 Merck Patent Gmbh Pyrazolo[4,3-d]pyrimidine
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
DE602005011286D1 (en) 2004-07-05 2009-01-08 Astellas Pharma Inc Pyrazolopyridinderivate
WO2006044821A1 (en) 2004-10-19 2006-04-27 Sb Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto
WO2006084251A2 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune reponse modifiers
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
RU2402549C3 (ru) 2005-04-14 2022-03-10 Оцука Фармасьютикал Ко., Лтд. Пиперазин-замещенные бензотиофены для лечения психических расстройств
CN101309909B (zh) 2005-12-22 2012-11-14 纽朗制药有限公司 作为钙和/或钠通道调节剂的2-苯基乙基氨基衍生物
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
EP2089034A4 (en) * 2006-12-05 2010-07-28 Intra Cellular Therapies Inc NEW USES
EP2124944B1 (en) 2007-03-14 2012-02-15 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridine derivatives as phosphodiesterase inhibitors
MA32940B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
JP5917394B2 (ja) 2009-06-10 2016-05-11 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法
AU2011289629B2 (en) 2010-08-12 2014-07-03 Eli Lilly And Company Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EA034193B1 (ru) 2011-04-21 2020-01-15 Оригенис Гмбх Гетероциклические соединения в качестве ингибиторов киназ
CN104379578B (zh) 2012-03-19 2017-06-09 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲lrrk2抑制劑的芳基吡咯并吡啶衍生化合物
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
MX2016010777A (es) 2014-02-19 2016-10-26 H Lundbeck As 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer.
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
US20170273985A1 (en) 2014-09-18 2017-09-28 Sunovion Pharmaceuticals Inc. Tricyclic derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 H 朗德貝克公司 作爲pde1抑制劑之三唑並吡酮
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
US20180044343A1 (en) 2015-03-16 2018-02-15 Sumitomo Dainippon Pharma Co., Ltd. Bicyclic imidazolo derivative
US20160311831A1 (en) 2015-04-22 2016-10-27 H. Lundbeck A/S Imidazotriazinones as PDE1 Inhibitors
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
BR112017007472A2 (pt) 2015-08-12 2018-01-23 H Lundbeck As 2-amino-3-fluoro-3-(fluoro metil)-6-metil-6-fenil- 3,4,5,6-tetra-hidropiridinas como inibidores de bace1
WO2017100276A1 (en) 2015-12-08 2017-06-15 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
GB2563730B (en) 2015-12-09 2021-09-15 Ford Global Tech Llc Alert for left-behind mobile device
WO2017172795A1 (en) 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
WO2019115566A1 (en) 2017-12-14 2019-06-20 H. Lundbeck A/S Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US10766893B2 (en) 2017-12-20 2020-09-08 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
TW201927784A (zh) * 2017-12-20 2019-07-16 丹麥商H 朗德貝克公司 作為pde1抑制劑之大環
US11535611B2 (en) * 2017-12-20 2022-12-27 H. Lundbeck A/S Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors

Also Published As

Publication number Publication date
US11634416B2 (en) 2023-04-25
HUE057202T2 (hu) 2022-04-28
ES2899868T3 (es) 2022-03-15
CL2020001548A1 (es) 2020-09-25
CN111465410B (zh) 2022-10-25
PT3723807T (pt) 2021-11-26
EP3723807B1 (en) 2021-10-20
ZA202003514B (en) 2022-12-21
CA3085201A1 (en) 2019-06-20
CN111465410A (zh) 2020-07-28
LT3723807T (lt) 2021-12-10
AU2018385453A1 (en) 2020-07-02
EP3723807A1 (en) 2020-10-21
BR112019016815A2 (pt) 2020-04-07
IL275290A (en) 2020-07-30
JP2021506775A (ja) 2021-02-22
AU2018385453B2 (en) 2024-02-08
AR113931A1 (es) 2020-07-01
HRP20211784T1 (hr) 2022-02-18
RU2020118913A (ru) 2022-01-14
MX2020006174A (es) 2022-09-27
KR20200099154A (ko) 2020-08-21
PL3723807T3 (pl) 2022-01-24
SG11202005361RA (en) 2020-07-29
WO2019115566A1 (en) 2019-06-20
RS62551B1 (sr) 2021-12-31
JP7261801B2 (ja) 2023-04-20
US20200385381A1 (en) 2020-12-10
IL275290B2 (en) 2023-06-01
CO2020007129A2 (es) 2020-06-19
CY1124751T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
ZA201802976B (en) N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
HK1249502A1 (zh) 吡啶並[3,4-d]嘧啶衍生物及其藥學上可允許的鹽
ZA202003514B (en) Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
IL275293A (en) Combined treatments that include administration of H1 - pyrazolo[4, 3-B]pyridines
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
SI3478681T1 (sl) 1h-pirazolo(4,3-b)piridini kot inhibitorji pde1
HK1225723A1 (zh) 取代的咪唑並[1,2-a]吡啶甲酰胺及其用途
IL252578B (en) History of 1h- pyrazolo (3.4-c) [5.1] naphthyridine 4-(5h)-one and pharmaceutical preparations containing them
HUS2200054I1 (hu) 2-fluor-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-B][1,2,4]triazin-2-il]benzamid tablettás kiszerelése
IL274868A (en) History of imidazopyridine and their use as medicine
ZA201704727B (en) New imidazo[1,2-a]quinoxalines and derivates thereof for the treatment of cancer